🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder

RecruitingNAAges 18 Years - 65 YearsAllPolytechnic Institute of Porto
NCT07474974 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in treatment-resistant depression (TRD). We also aim to assess the impact of TMS treatment on RGCs and ipRGCs in TRD patients, investigating associations with clinical improvements and cognitive status. A clinical trial involving 44 patients with treatment-resistant depression (TRD) will be conducted. All participants will receive rTMS targeting the dorsolateral prefrontal cortex (DLPFC). Data will be collected pre- and post-intervention, as well as at a 2-month follow-up, using multiple outcome measures, including the post-illumination pupil response (PIPR). The project seeks to confirm the effectiveness of TMS and the potential of RGCs/ipRGCs as predictors of treatment response, t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of MDD, confirmed via the structured clinical interview; * TRD type; * Age between 18-65 years; * Visual acuity of 20/32 or better. Exclusion Criteria: * Prior rTMS treatment; * Contraindications for TMS; * Psychiatric disorders other than MDD; * Systemic diseases affecting the eyes (e.g., diabetes mellitus); * Ocular conditions; * Head injuries causing loss of consciousness; * Current or past alcohol/substance dependence within 6 months; * Neurodegenerative diseases; * Major neurological illnesses; * Use of medications affecting iris mechanics or the autonomic nervous system.
💊

What it tests

  • Repetitive transcranial magnetic stimulation (rTMS)
📍

Where

1 site
RISE-Health, Center for Translational Health and Medical Biotechnology Research (TBIO), School of Health, Polytechnic of Porto
Porto, Portugal
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy